Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 10;5(3):e532. doi: 10.1097/HS9.0000000000000532

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.

PMC Copyright notice

Figure 5. — Outcome according to BMI difference between diagnosis and allogeneic HSCT (ΔBMI > –2 vs ≤ –2) within the 3 ELN2017 genetic risk groups in AML patients receiving allogeneic HSCT (n = 369). (A), Nonrelapse mortality and (B) overall survival in ELN2017 favorable-risk patients (n = 83). (C), Nonrelapse mortality and (D) overall survival in ELN2017 intermediate-risk patients (n = 98). (E), Nonrelapse mortality and (F) overall survival in ELN2017 adverse-risk patients (n = 127). AML = acute myeloid leukemia; BMI = body mass index; ELN = European LeukemiaNet; HSCT = hematopoietic stem cell transplantation.